About: Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
Author
Bibliographic Citation
  • Löwenberg Bob, Muus Petra, Ossenkoppele Gert, Rousselot Philippe, Cahn Jean-Yves, Ifrah Norbert, Martinelli Giovanni, Amadori Sergio, Berman Ellin, Sonneveld Pieter, Jongen-Lavrencic Mojca, Rigaudeau Sophie, Stockman Paul, Goudie Alison, Faderl Stefan, Jabbour Elias, Kantarjian Hagop. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.. Blood, American Society of Hematology, 2011, 118 (23), pp.6030-6. ⟨10.1182/blood-2011-07-366930⟩
  • Rousselot Philippe, Cahn Jean-Yves, Ifrah Norbert, Martinelli Giovanni, Amadori Sergio. Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.. Blood, American Society of Hematology, 2011, 118 (23), pp.6030-6. ⟨10.1182/blood-2011-07-366930⟩
Title
  • Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
dc:date
  • 2011
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software